XML 42 R32.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 7 - Stockholders' Equity (Deficit) (Details Textual)
3 Months Ended
Feb. 12, 2016
USD ($)
$ / shares
shares
Mar. 31, 2016
USD ($)
$ / shares
shares
Mar. 31, 2015
USD ($)
Dec. 31, 2015
shares
The 2006 Plan [Member] | Employee Stock Option [Member] | Minimum [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period   1 year    
The 2006 Plan [Member] | Employee Stock Option [Member] | Maximum [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period   5 years    
The 2006 Plan [Member] | Employee Stock Option [Member] | Chief Financial Officer [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period 3 years      
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period 10 years      
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting, Number of Monthly Installments 35      
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting, Monthly Installment, Shares 2,778      
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting, Final Monthly Installment, Shares 2,770      
The 2006 Plan [Member] | Employee Stock Option [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized   2,000,000    
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period   10 years    
The 2006 Plan [Member] | Chief Financial Officer [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 100,000      
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares $ 1.25      
The 2006 Plan [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number   1,391,145    
Employee Stock Option [Member]        
Allocated Share-based Compensation Expense | $   $ 102,908 $ 24,801  
Protagenic Therapeutics Inc [Member] | Private Placement [Member]        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 3,403,367      
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 1.05      
Protagenic Therapeutics Inc [Member] | Predecessor Warrants [Member]        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 295,945      
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 1.25      
Protagenic Therapeutics Inc [Member] | Placement Agent Warrants [Member]        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 127,346      
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 1.25      
Protagenic Therapeutics Inc [Member]        
Business Combination, Stock Warrant Conversion Ratio 1      
Debt Instrument, Face Amount | $ $ 665,000      
Debt Instrument, Increase, Accrued Interest | $ $ 35,000      
Class of Warrant or Right, Expiration Period 5 years      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number   1,391,145   1,707,744
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross   100,000    
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares   $ 1.25